Hormonal
Mistimed sleep (sleeping during the day) causes a massive arrhythmicity in peripheral gene expression, with 97% of rhythmic genes becoming arrhythmic in humans.
If you must work night shifts or sleep during the day, recognize that your body's gene expression rhythms are severely disrupted. This is not just about feeling groggy; it is a state of molecular desynchronization. Mitigate this by controlling light exposure, timing meals carefully, and prioritizing sleep quality when possible.
In humans, sleep restriction leads to a 1.9% reduction in circadian transcripts in whole blood, and when sleep is displaced to the daytime, 97% of rhythmic genes become arrhythmic and one-third of all genes show changes in temporal expression profiles.
Why this rating
Based on human transcriptomic data from Archer et al. (2014) cited in the review.
Source
How sleep and wakefulness influence circadian rhythmicity: effects of insufficient and mistimed sleep on the animal and human transcriptome
Simon Archer et al. · Journal of Sleep Research · 2015
DOI 10.1111/jsr.12307
More from this paper
- Insufficient or mistimed sleep disrupts circadian gene expression rhythms in peripheral tissues (e.g., liver, blood), leading to metabolic and immune dysregulation, while the central pacemaker (SCN) remains largely unaffected.Good
- Sleep disruption is associated with an increased risk of metabolic syndrome, type-2 diabetes, and certain cancers through mechanisms involving altered gene expression, hormone levels, and immune response.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →